Cite
HARVARD Citation
Lawitz, E. et al. (2018). Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Antiviral therapy. 23 (4), pp. 325-334. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lawitz, E. et al. (2018). Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Antiviral therapy. 23 (4), pp. 325-334. [Online].